Gravina and others used a selective inhibition of XPO1, Selinexor (KPT-330), to demonstrate that XPO1 inhibition affects the metastatic potential of PCa cells using one model of intraprostatic tumor growth and two models of bone metastasis (Gravina et al., 2014). The gene discussed is XPO1; the disease is neoplasm.